Dermira, a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, announced positive Phase IIb study results for DRM04, its proprietary topical anticholinergic product, in patients with axillary hyperhidrosis, or excessive underarm sweating.